In summary, our data supported the assertion that secondary mutation in RAD51D can not only reverse a loss-of-function change of RAD51D that was disrupted by the inherited defect in an ovarian cancer patient but also reinstitute HR function and contribute to the development of clinical resistance to PARPi. The gene discussed is RAD51D; the disease is ovarian carcinoma.